Marina Biotech (NASDAQ: [[ticker:MRNA]]), the Bothell, WA-based developer of RNA-based therapies, said today it has raised $3.3 million through a securities offering. Investors in the deal, who bought 1.8 million shares at $1.84 apiece, also got a subscription unit to buy another 2.4 million shares at any time over the next 16 months for no more than $2.21 a share, Marina said. If investors buy those shares, the company could raise another $5.4 million.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
